Cargando…
Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study
BACKGROUND AND OBJECTIVE: AFRICAT is a prospective cohort study intending to develop an atrial fibrillation (AF) screening program through the combination of blood markers, rhythm detection devices, and long-term monitoring in our community. In particular, we aimed to validate the use of NT-proBNP,...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398023/ https://www.ncbi.nlm.nih.gov/pubmed/35998199 http://dx.doi.org/10.1371/journal.pone.0273571 |
_version_ | 1784772253502668800 |
---|---|
author | Palà, Elena Bustamante, Alejandro Clúa-Espuny, Josep Lluis Acosta, Juan González-Loyola, Felipe Santos, Sara Dos Ribas-Segui, Domingo Ballesta-Ors, Juan Penalba, Anna Giralt, Marina Lechuga-Duran, Iñigo Gentille-Lorente, Delicia Pedrote, Alonso Muñoz, Miguel Ángel Montaner, Joan |
author_facet | Palà, Elena Bustamante, Alejandro Clúa-Espuny, Josep Lluis Acosta, Juan González-Loyola, Felipe Santos, Sara Dos Ribas-Segui, Domingo Ballesta-Ors, Juan Penalba, Anna Giralt, Marina Lechuga-Duran, Iñigo Gentille-Lorente, Delicia Pedrote, Alonso Muñoz, Miguel Ángel Montaner, Joan |
author_sort | Palà, Elena |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: AFRICAT is a prospective cohort study intending to develop an atrial fibrillation (AF) screening program through the combination of blood markers, rhythm detection devices, and long-term monitoring in our community. In particular, we aimed to validate the use of NT-proBNP, and identify new blood biomarkers associated with AF. Also, we aimed to compare AF detection using various wearables and long-term Holter monitoring. METHODS: 359 subjects aged 65–75 years with hypertension and diabetes were included in two phases: Phase I (n = 100) and Phase II (n = 259). AF diagnosis was performed by baseline 12-lead ECG, 4 weeks of Holter monitoring (Nuubo(TM)), and/or medical history. An aptamer array including 1310 proteins was measured in the blood of 26 patients. Candidates were selected according to p-value, logFC and biological function to be tested in verification and validation phases. Several screening devices were tested and compared: AliveCor, Watch BP, MyDiagnostick and Fibricheck. RESULTS: AF was present in 34 subjects (9.47%). The aptamer array revealed 41 proteins with differential expression in AF individuals. TIMP-2 and ST-2 were the most promising candidates in the verification analysis, but none of them was further validated. NT-proBNP (log-transformed) (OR = 1.934; p<0.001) was the only independent biomarker to detect AF in the whole cohort. Compared to an ECG, WatchBP had the highest sensitivity (84.6%) and AUC (0.895 [0.780–1]), while MyDiagnostick showed the highest specificity (97.10%). CONCLUSION: The inclusion and monitoring of a cohort of primary care patients for AF detection, together with the testing of biomarkers and screening devices provided useful lessons about AF screening in our community. An AF screening strategy using rhythm detection devices and short monitoring periods among high-risk patients with high NT-proBNP levels could be feasible. |
format | Online Article Text |
id | pubmed-9398023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-93980232022-08-24 Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study Palà, Elena Bustamante, Alejandro Clúa-Espuny, Josep Lluis Acosta, Juan González-Loyola, Felipe Santos, Sara Dos Ribas-Segui, Domingo Ballesta-Ors, Juan Penalba, Anna Giralt, Marina Lechuga-Duran, Iñigo Gentille-Lorente, Delicia Pedrote, Alonso Muñoz, Miguel Ángel Montaner, Joan PLoS One Research Article BACKGROUND AND OBJECTIVE: AFRICAT is a prospective cohort study intending to develop an atrial fibrillation (AF) screening program through the combination of blood markers, rhythm detection devices, and long-term monitoring in our community. In particular, we aimed to validate the use of NT-proBNP, and identify new blood biomarkers associated with AF. Also, we aimed to compare AF detection using various wearables and long-term Holter monitoring. METHODS: 359 subjects aged 65–75 years with hypertension and diabetes were included in two phases: Phase I (n = 100) and Phase II (n = 259). AF diagnosis was performed by baseline 12-lead ECG, 4 weeks of Holter monitoring (Nuubo(TM)), and/or medical history. An aptamer array including 1310 proteins was measured in the blood of 26 patients. Candidates were selected according to p-value, logFC and biological function to be tested in verification and validation phases. Several screening devices were tested and compared: AliveCor, Watch BP, MyDiagnostick and Fibricheck. RESULTS: AF was present in 34 subjects (9.47%). The aptamer array revealed 41 proteins with differential expression in AF individuals. TIMP-2 and ST-2 were the most promising candidates in the verification analysis, but none of them was further validated. NT-proBNP (log-transformed) (OR = 1.934; p<0.001) was the only independent biomarker to detect AF in the whole cohort. Compared to an ECG, WatchBP had the highest sensitivity (84.6%) and AUC (0.895 [0.780–1]), while MyDiagnostick showed the highest specificity (97.10%). CONCLUSION: The inclusion and monitoring of a cohort of primary care patients for AF detection, together with the testing of biomarkers and screening devices provided useful lessons about AF screening in our community. An AF screening strategy using rhythm detection devices and short monitoring periods among high-risk patients with high NT-proBNP levels could be feasible. Public Library of Science 2022-08-23 /pmc/articles/PMC9398023/ /pubmed/35998199 http://dx.doi.org/10.1371/journal.pone.0273571 Text en © 2022 Palà et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Palà, Elena Bustamante, Alejandro Clúa-Espuny, Josep Lluis Acosta, Juan González-Loyola, Felipe Santos, Sara Dos Ribas-Segui, Domingo Ballesta-Ors, Juan Penalba, Anna Giralt, Marina Lechuga-Duran, Iñigo Gentille-Lorente, Delicia Pedrote, Alonso Muñoz, Miguel Ángel Montaner, Joan Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study |
title | Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study |
title_full | Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study |
title_fullStr | Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study |
title_full_unstemmed | Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study |
title_short | Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study |
title_sort | blood-biomarkers and devices for atrial fibrillation screening: lessons learned from the africat (atrial fibrillation research in catalonia) study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398023/ https://www.ncbi.nlm.nih.gov/pubmed/35998199 http://dx.doi.org/10.1371/journal.pone.0273571 |
work_keys_str_mv | AT palaelena bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT bustamantealejandro bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT cluaespunyjoseplluis bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT acostajuan bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT gonzalezloyolafelipe bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT santossarados bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT ribasseguidomingo bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT ballestaorsjuan bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT penalbaanna bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT giraltmarina bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT lechugaduraninigo bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT gentillelorentedelicia bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT pedrotealonso bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT munozmiguelangel bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy AT montanerjoan bloodbiomarkersanddevicesforatrialfibrillationscreeninglessonslearnedfromtheafricatatrialfibrillationresearchincataloniastudy |